Medpace Hits All-Time High – Record Orders of $873 Million Fuel Growth Story
Reading Time: 3 minutes
Medpace enables small biotech companies to conduct global drug studies without their own international study networks. More successful tenders and the recovery of classic cancer studies strengthen the order pipeline. Proprietary AI models facilitate image analyses. Higher profit targets and share buybacks create additional opportunities. Medpace Holdings (MEDP) reached a new all-time high of $693.97 on October 28. Since the beginning of the year, the stock has increased by about 23%. Now, record orders could accelerate revenue growth....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
